Institute of hepatobiliary surgery,Southwest Hospital Report issue

Academic/Hospital

Organization Overview

First Clinical Trial
2016
NCT03790059
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Institute of hepatobiliary surgery,Southwest Hospital

Active Ingredients

Drugs in Other Trials (1)

Recombinant Human Type-5 Adenovirus (Gendicine) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1